



**Subscribe** to follow us **@ILPMP** on YouTube

[View as Webpage](#)

## New Public Act 103-1064 Requires Stricter Documentation for Authorized Requestors Obtaining Confidential ILPMP Prescription Data

Public Act 103-1064, effective February 7, 2025, has been incorporated into the Illinois Controlled Substance Act. This legislation required stricter requirements for obtaining confidential information from the ILPMP aiming to ensure all requests are legally documented, reducing the risk of unauthorized access to sensitive patient data.

Under Public Act 103-1064, the applicant must:

1. Have reason to believe a violation involving a controlled substance had occurred under state or federal law.
2. Demonstrate that the requested information was reasonably related to the investigation, adjudication, or prosecution of the violation.
3. Provide a valid court order or subpoena.
4. An administrative subpoena will only be accepted if issued by the Department of Financial and Professional Regulation (IDFPR).
5. Department of Children and Family Service (DCFS) requests do not require court order or subpoena.

Other changes addressed include:

- Specifies that decisions regarding treatment with controlled substances, including opioids, should not be restricted by CDC Morphine Milligram Equivalent (MME) guidelines, unless required under federal law.
- Language stating ILPMP Peer Review Committee (PRC) retains full authority to use MME threshold for clinical oversight and monitoring.
- Adds trained designee may review and release ILPMP information upon review.
- Confidential information shared from Opioid Treatment Programs or confidential information otherwise protected under federal confidentiality of

substance use disorder patient records regulations under 42 CFR Part 2 shall not be included in the information shared.

Due to these recent legislative changes, the formerly known Law Enforcement Online Request (LEOR) portal is no longer available. Law enforcement entities are no longer permitted to log in and submit requests online. See link below with revised guidelines regarding process changes.

[More Information on Public Act 103-1064](#)

[Authorized Data Requestor Guidance](#)

## ILPMP Updates Frequently Asked Questions (FAQ) Section for Improved Clarity

The ILPMP has recently updated its FAQ section to provide clearer guidance for healthcare providers and dispensers. The enhanced FAQ addresses key topics, including:

- [Registration and Access](#): Detailed steps for users to register and navigate the ILPMP.
- [Data Submission Requirements](#): Clarification on the necessity of submitting timely prescription data.
- [Designee Management](#): Instructions on adding, removing, and verifying designees.
- [IL PMPnow Integration](#): Detailed information on definitions, cost, access, etc. for integrating ILPMP into healthcare workflow.
- [Opioid Treatment Program \(OTP\) Reporting](#): Information on the integration of OTP data into the ILPMP.

These updates aim to enhance user experience and ensure compliance with state regulations. For more detailed information, users are encouraged to visit [ILPMP.org](https://www.ilpmp.org), FAQ page.



## Access Narcan Project Ships Over 1 Million, 2- Dose Boxes of Narcan



In January of 2025, Illinois hit an important milestone. Since July 2021, the Illinois Department of Human Services/Division of Substance Use Prevention and Recovery (IDHS/SUPR) has shipped over 1 million 2-dose boxes of Narcan across the state of Illinois through the Access Narcan project.

The Access Narcan project provides no-cost nasal naloxone to organizations that are doing outreach, distribution, and engaging with those at risk of overdose through our Drug Overdose Prevention Program (DOPP).

The Substance Abuse and Mental Health Services Administration (SAMHSA) requested all states to begin saturating their states with naloxone two years ago. Illinois was already ahead of the curve and has exceeded SAMHSA's saturation targets. Once shipped, these boxes of nasal naloxone are distributed to those most at risk of overdose, their friends, and families.

See the IDHS/SUPR Smart Alert for more details.

[Narcan Smart Alert](#)

	OPVEE® (nalmefene HCl nasal spray)	naloxone HCl
		
Packaging and dose	Two unit-dose devices per pack 2.7mg/0.1mL single dose nasal spray	Two unit-dose devices per pack naloxone 4mg/0.1mL Kloxxado 8mg/0.1mL
Approval	May 22, 2023 Indicated for age 12YO and older	naloxone - 1971 Kloxxado - April 30, 2021
onset and peak effect	2.5-5 min 15 min to peak	2-3 min 15 - 20 min to peak
Duration	1-4 hours	30-90 min
Half-life	11 hours	2 hours
Potential Benefits	<ul style="list-style-type: none"> <li>• Similar duration to most opioids</li> <li>• Less risk of OD relapse</li> <li>• More potent mu-opioid receptor antagonism</li> </ul>	<ul style="list-style-type: none"> <li>• Shorter duration of withdrawal symptoms</li> <li>• Widely available including OTC</li> <li>• Well known and inexpensive</li> </ul>
Potential Drawbacks	<ul style="list-style-type: none"> <li>• Longer duration extends withdrawal symptoms</li> <li>• Only for 12YO and older</li> <li>• Unknown cost &amp; availability</li> </ul>	<ul style="list-style-type: none"> <li>• May need multiple doses</li> <li>• Short duration increase risk of relapse</li> <li>• High potency synthetic opioids may require more than 2 doses</li> </ul>

Opvee / Nalmefene prescribing information

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2023/217470Orig1s000.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf)


Naloxone prescribing information

<https://www.narcan.com/wp-content/uploads/2022/06/Gen2-Prescribing-Information.pdf>

## Educational Resources

### Illinois Opioid Overdose Reversal Agent Standardized Procedure

Illinois Opioid Overdose Reversal Agent Standardized Procedure allows pharmacies and certain entities to dispense / distribute opioid reversal agents under a standing order in the State of Illinois. This short animated video briefly discusses these reversal agents and the standardized procedure. Brought to you by the Southern Illinois University Edwardsville School of Pharmacy and the Illinois Prescription Monitoring Program.



## Newly Released, FREE, Continuing Education Available for Pharmacists and Pharmacy Technicians on the Importance of PMP Data Integrity

Take advantage of this free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity.

Visit <https://ce.talemhealth.com/a/MWEORC>

**If you received credit for this CE prior to 10/22/24, you are still able to retake the CE and receive credit.**


[Click for more CE Information](#)

# Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

A three-hour program designed to meet the educational needs for physicians, nurses, and pharmacists. The program is accredited in 6, 30-minute modules.

SOUTHERN ILLINOIS UNIVERSITY  
EDWARDSVILLE

**ILPMP**  
Illinois Prescription Monitoring Program



## Continuing Education Program

### Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder


Session 1: Pain taxonomy, pathogenesis, and assessment  
Session 2: Developing a patient-centered pain treatment plan  
Session 3: Non-opioid analgesics: Evidence and clinical Pearls  
Session 4: Opioid analgesics: From A to Z  
Session 5: Clinical use of opioids: Safe prescribing and monitoring  
Session 6: The exit strategy: When the treatment becomes the problem

Faculty:  
June Oliver, MSN, APRN/CNS  
Laura Meyer-Junco, PharmD, BCPS, FASCP  
Chris Herndon, PharmD, BCACP, FCCP  
Camille Dunkley, MD, MHA, MS  
Noah Cooperstein, MD

[Prescriber Registration](#)

## ILPMP.ORG & IL PMPnow Monthly Data

### WEBSITE DATA JANUARY 2025



# Contact Information

If you have questions about the information that appears in this update or suggestions for future content, please email [dhs.pmp@illinois.gov](mailto:dhs.pmp@illinois.gov). Visit [www.ilpmp.org](http://www.ilpmp.org) for more information.



*The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.*

Illinois Prescription Monitoring Program | 401 North Fourth Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!